INSP Stock Recent News

Inspire Medical Systems (INSP) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of a loss of $0.14 per share. This compares to loss of $0.41 per share a year ago.

Inspire Reports Year-over-Year Revenue Growth of 30% in the Second Quarter Inspire Reports Year-over-Year Revenue Growth of 30% in the Second Quarter

MINNEAPOLIS, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that its Board of Directors has authorized the repurchase of up to $150.0 million of the company's outstanding shares of common stock.

Inspire Medical (INSP) secures FDA approval for its advanced Inspire V therapy system, featuring an innovative neurostimulator and Bluetooth technology for enhanced patient and physician control.

Besides Wall Street's top -and-bottom-line estimates for Inspire (INSP), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.

MINNEAPOLIS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the FDA approval of the Inspire V therapy system which includes the next generation neurostimulator and the associated Bluetooth® patient remote and physician programmer.

Inspire Medical Systems (INSP) shares rose Monday after the maker of an implanted device to treat sleep apnea released preliminary results and updated guidance that beat forecasts.

MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced certain preliminary, unaudited results for the quarter ended June 30, 2024, and updated full year 2024 revenue outlook. The company plans to report its complete results and host its earnings conference call for the second quarter of 2024 on August 6, 2024.

MINNEAPOLIS, July 23, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), announced today the publication of the reimbursement of Inspire therapy in France.

Inspire Medical's (INSP) receipt of the latest CE mark certification will likely enable it to continue to deliver Inspire products globally.